---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-029510"
form_type: "8-K"
ticker: "FLGT"
cik: "0001674930"
company_name: "Fulgent Genetics, Inc."
filed_at: "2025-02-28T23:59:59+00:00"
generated_at: "2026-05-25T23:37:14.069644+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Fulgent Genetics reports Q4 2024 core revenue up 14% YoY to $76.0M; full year core revenue up 7% to $281.2M

## Summary
- Full year total revenue $283.5M; core revenue (ex-COVID) grew 7% to $281.2M.
- GAAP net loss of $42.7M ($1.41 per share) for FY 2024; non-GAAP income $15.0M ($0.49 per share).
- Q4 2024 total revenue $76.2M; core revenue up 14% to $76.0M; GAAP loss $5.9M, non-GAAP income $1.2M.
- Ended 2024 with $828.6M cash & investments ($26.87/share); cash from ops $21.1M.

## SEC filing metadata
- accession: 0000950170-25-029510
- form_type: 8-K
- ticker: FLGT
- cik: 0001674930
- company_name: Fulgent Genetics, Inc.
- filed_at: 2025-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674930/000095017025029510/0000950170-25-029510-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674930/000095017025029510/flgt-20250228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-029510
- JSON: https://secwatch.observer/filing/0000950170-25-029510.json
- Plain text: https://secwatch.observer/filing/0000950170-25-029510.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.